Abstract
N-(4-Hydroxyphenyl)-retinamide (4-HPR, Fenretinide) is a synthetic retinoid with cytotoxicity in acute lymphoblastic leukemia (ALL) cell lines. Since ALL is a disease of the bone marrow, a hypoxic tissue compartment, and it has been reported that there is an antagonistic effect of hypoxia on many chemotherapeutic agents, our purpose was to observe whether hypoxia is able to inhibit the effect of 4-HPR for ALL cell lines and to investigate its mechanisms of antagonism to 4-HPR. Cytotoxicity was measured by MTT method, and apoptosis was measured by flow cytometry. Mitochondrial membrane potential (DeltaPsim) was detected by JC1 staining and flow cytometry. Protein expression was analyzed by western blotting. Hypoxia (2% O2) induced 4-HPR resistance in the tested two ALL cell lines (Molt-4 and Molt-3), with at least a 2.8-fold increase in IC50 values (P<0.01) compared with the IC50 values in normoxia (20% O2). Apoptotic detection showed that 2% O2 significantly suppressed 4-HPR-induced apoptosis and the percentages of 4-HPR-induced apoptotic cells at 12 and 24 h were 1.2 and 11.0%, respectively, compared with 12.6 and 76.3% in 20% O2. In addition, in 20% O2, but not in 2% O2, 4-HPR obviously downregulated the protein expression of...Continue Reading
References
Feb 6, 1991·Journal of the National Cancer Institute·J M Brown, A Koong
Jul 28, 1997·The Journal of Cell Biology·M ManciniD M Hockenbery
Apr 29, 1998·Journal of the National Cancer Institute·A L SabichiM J Birrer
Aug 26, 1998·Biochimica Et Biophysica Acta·S A SusinG Kroemer
Feb 16, 1999·Nature·S A SusinG Kroemer
Apr 17, 1999·The Journal of Biological Chemistry·H ZouX Wang
Jul 7, 1999·Journal of the National Cancer Institute·B J MaurerC P Reynolds
Nov 26, 1999·Molecular Pharmacology·Y R ChenT H Tan
Mar 4, 2000·Cancer·G R BuchananD Pinkel
Aug 10, 2000·Archives of Biochemistry and Biophysics·C F YangC N Ong
Aug 26, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G U Dachs, G M Tozer
Sep 30, 2000·Experimental Cell Research·P E LovatC P Redfern
Oct 14, 2000·Cell Research·Y L Yang, X M Li
Nov 28, 2000·International Journal of Cancer. Journal International Du Cancer·P E LovatC P Redfern
Mar 10, 2001·Journal of the National Cancer Institute·A SenchenkovM C Cabot
Mar 30, 2001·The Journal of Biological Chemistry·M KondoK Uchida
Sep 19, 2001·The Journal of Clinical Investigation·M MilellaM Andreeff
Jan 5, 2002·Experimental Cell Research·Hong LinBen D Chen
May 3, 2002·Leukemia·P H O'DonnellB J Maurer
Jan 23, 2003·Leukemia Research·Stefan FaderlZeev Estrov
Feb 20, 2003·Leukemia·M B MirandaD E Johnson
May 1, 1963·Annals of Internal Medicine·J L GRANT, B SMITH
Nov 18, 2003·British Journal of Haematology·Judith M ChessellsIan M Hann
Mar 12, 2004·Cancer Letters·C Patrick ReynoldsRichard N Kolesnick
Aug 4, 2004·Cancer Research·Sandeep BatraBarry J Maurer
Aug 5, 2004·The Journal of Biological Chemistry·Shyra J GardaiPeter M Henson
Aug 9, 2005·Free Radical Biology & Medicine·Wei-Xing GuoRobert H Broyles
Citations
Jul 16, 2010·Molecular Cancer·Lionel FlamantCarine Michiels
Jan 22, 2015·Molecular Medicine Reports·Shanshan ShiShenglin Ma
Jul 30, 2014·Biochemical Pharmacology·Nimesh Mody, George D Mcilroy
Jan 8, 2014·Antioxidants & Redox Signaling·Ji CaoBo Yang
Dec 30, 2009·Molecular Pharmacology·Laura M HighRichard B Lock
Dec 4, 2013·The Journal of Biological Chemistry·Ranjit Kumar MehtaAvinash Sonawane